# Michael Millward

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michael-millward/

## Facts

| Field | Value |
| --- | --- |
| Citations | 16,268 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 62 |
| i10-index | 202 |
| Last Known Institution | GlaxoSmithKline (Australia) |
| OpenAlex ID | https://openalex.org/A5079833339 |
| ORCID iD | https://orcid.org/0000-0002-1744-1617 |
| Works | 454 |

## Researcher papers

- [Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-nivolumab-versus-ipilimumab-in-resected-stage-iiib-c-and-stage-iv/)
- [Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor](https://scholariq.org/papers/phase-ii-study-of-the-mek1-mek2-inhibitor-trametinib-in-patients-with-metastatic/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

## Researcher university

- [GlaxoSmithKline (Australia)](https://scholariq.org/institutions/glaxosmithkline-australia/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.